Meropenem
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Meropenem: From Broad-Spectrum Antibacterial Therapy to Bacterial Arthritis
One-Sentence Summary
Meropenem is a carbapenem-class broad-spectrum antibacterial agent; detailed original licensed indication data is not available in this evidence pack. The TxGNN model predicts it may be effective for Bacterial Arthritis, with 1 clinical trial (indirect relevance only) and 20 publications — mostly case reports and observational studies — currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this evidence pack (see Data Gaps below) |
| Predicted New Indication | Bacterial Arthritis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L3 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, meropenem belongs to the carbapenem class of broad-spectrum beta-lactam antibiotics; its efficacy in serious bacterial infections is well established in general clinical use, and mechanistically it may be applicable to bacterial (septic) arthritis.
Meropenem has activity against the common Gram-positive and Gram-negative aerobic organisms — and some anaerobes — that cause septic arthritis, and is frequently used empirically or as an alternative agent when multidrug-resistant (MDR) pathogens are suspected. However, no dedicated prospective clinical trial has been conducted specifically for this indication; the supporting literature consists largely of case reports, retrospective cohorts, and in-vitro/orthopaedic-device studies rather than interventional trials designed to test efficacy in bacterial arthritis directly.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01371656 | Phase 3 | Completed | 624 | Evaluated levofloxacin (not meropenem) to prevent bacteraemia in children with acute leukaemia/HSCT; relevance graded C — not a meropenem-specific or arthritis-specific trial, included here for completeness only |
No clinical trial directly evaluates meropenem for bacterial arthritis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38139869 | 2023 | Case Report | Pharmaceuticals (Basel) | Native hip septic arthritis due to Bacillus pumilus and Paenibacillus barengoltzii managed successfully with long-term antibiotic therapy |
| 39489417 | 2024 | Case Series | Indian J Med Microbiol | Retrospective review of 22 musculoskeletal melioidosis cases; septic arthritis and osteomyelitis isolates were susceptible to meropenem |
| 35146367 | 2021 | Cohort Study | Le Infezioni in Medicina | Retrospective cohort characterising osteoarticular melioidosis, a rare focal bone/joint presentation |
| 39193962 | 2024 | Observational | Clinical Laboratory | Analysis of pathogen distribution and antimicrobial resistance in bone and joint infections among young children |
| 38134096 | 2023 | Case Report | Medicine | Campylobacter fetus-induced psoas abscess in a patient with gouty arthritis |
| 37713001 | 2024 | Observational | Eur J Orthop Surg Traumatol | Antibiogram development for empiric antibiotic prescribing in non-spinal orthopaedic infections |
| 33857030 | 2021 | In Vitro Study | J Bone Joint Surg Am | Thermal stability and elution kinetics of meropenem (among others) in PMMA bone cement for orthopaedic infection |
| 38808002 | 2024 | Case Report | Frontiers in Public Health | Streptococcus suis meningitis case; noted pathogen can also cause arthritis |
| 36804370 | 2023 | Review | Int J Antimicrob Agents | Review of off-label vs. formal recommendations for antibiotics (including carbapenems) against MDR Gram-positive and Gram-negative bacteria |
| 40119266 | 2025 | Case Report | BMC Infect Dis | Septic shock caused by drug-resistant Edwardsiella tarda, with literature review |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence specific to bacterial arthritis is limited to case reports, small retrospective series, and in-vitro/device studies (Evidence Level L3); no clinical trial has directly tested meropenem for this indication. Critically, mechanism-of-action data and UK/local product label safety and contraindication information are both flagged as data gaps — one of which (label warnings/contraindications) is a Blocking gap that prevents even an initial safety screen (S1).
To proceed, the following is needed:
- Product label safety data — warnings and contraindications (Blocking gap, DG001)
- Detailed mechanism of action data to support mechanistic-relevance analysis (DG002)
- Prospective clinical evidence specifically evaluating meropenem in septic/bacterial arthritis
- Confirmation of UK marketing authorisation and licensing status, as this evidence pack currently shows no UK licences on record
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.